Evaluation Of Icatibant Reinjection Of Laryngeal Hereditary Angioedema Attacks: A Pooled Analysis Of Three Phase III Open-Label Extension Studies

被引：0
|
作者：
Baptista, Jovanna [1 ]
Bernstein, Jonathan A. [2 ]
Lumry, William R. [3 ]
Riedl, Marc A. [4 ]
机构：
[1] Shire, Lexington, MA USA
[2] Univ Cincinnati, Med Ctr, Div Immunol Allergy & Rheumatol, Cincinnati, OH 45267 USA
[3] Allergy & Asthma Specialists, Dallas, TX USA
[4] Univ Calif San Diego, La Jolla, CA 92093 USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2014年 / 133卷 / 02期
关键词：
D O I：
10.1016/j.jaci.2013.12.152
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
128
引用
收藏
页码：AB36 / AB36
页数：1
相关论文
共 50 条
  • [1] CHARACTERIZING HEREDITARY ANGIOEDEMA ATTACKS REQUIRING RE-INJECTION OF ICATIBANT: A POOLED ANALYSIS OF THREE PHASE III OPEN-LABEL EXTENSION STUDIES
    Bernstein, J.
    Lumry, W.
    Baptista, J.
    Riedl, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2013, 111 (05) : A49 - A50
  • [2] Analysis of icatibant reinjection rates for the treatment of laryngeal hereditary angioedema attacks in the FAST-3 open-label extension study
    Farkas, H.
    Bernstein, J. A.
    Lumry, W. R.
    Baptista, J.
    Riedl, M.
    Moldovan, D.
    ALLERGY, 2014, 69 : 53 - 53
  • [3] Evaluation of icatibant for the repeated treatment of hereditary angioedema attacks across three phase III open label extension studies
    Aberer, W.
    Lumry, W.
    Farkas, H.
    Bernstein, J. A.
    Bouillet, L.
    Baptista, J.
    Reidl, M.
    ALLERGY, 2013, 68 : 16 - 16
  • [4] Icatibant for laryngeal hereditary angioedema (HAE) attacks: patient/attack characteristics, reinjection rates and symptom outcomes across three open-label extension studies
    Aberer, W.
    Lumry, W.
    Bas, M.
    Bouillet, L.
    Baptista, J.
    Riedl, M.
    ALLERGY, 2014, 69 : 489 - 490
  • [5] Clinical Outcomes with Icatibant in the Open-Label Treatment of 45 Laryngeal Attacks of Hereditary Angioedema
    Riedl, M.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (02) : AB163 - AB163
  • [6] Icatibant is effective in the treatment of acute attacks of hereditary angioedema: updates on the open-label extension arm of a phase III clinical trial
    Bork, K.
    ALLERGY, 2009, 64 : 281 - 282
  • [7] Icatibant for the treatment of laryngeal attacks in hereditary angioedema: an update of the FAST-3 study and its open-label extension
    Moldovan, D.
    Toubi, E.
    Li, H.
    Reidl, M.
    ALLERGY, 2013, 68 : 120 - 120
  • [8] Patient satisfaction with icatibant during open-label treatment of hereditary angioedema attacks in the for angioedema subcutaneous treatment phase III trials
    Malbran, A.
    Aberer, W.
    Lumry, W.
    Reshef, A.
    Riedl, M.
    Cicardi, M.
    ALLERGY, 2011, 66 : 425 - 425
  • [9] A pooled analysis of three phase III trials to explore the efficacy of icatibant in the treatment of laryngeal attacks of type I and II hereditary angioedema
    Bas, M.
    Ritchie, B.
    Lumry, W.
    Aberer, W.
    ALLERGY, 2012, 67 : 197 - 198
  • [10] Icatibant for the treatment of repeated attacks of hereditary angioedema: FAST-3 trial open-label extension study phase
    Lumry, W.
    Levy, R.
    Li, H.
    Farkas, H.
    ALLERGY, 2013, 68 : 254 - 255
12345